Novel Resistance Mechanisms to Osimertinib Analysed by Whole-Exome Sequencing in Non-Small Cell Lung Cancer

References

• Howlader NNA, Krapcho M, Miller D, et al. eds. SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD; 2017.
   Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. doi:10.1056/NEJMoa090953020573926
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2015;373:1582.
   Web of Science ®Google Scholar
• Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR -mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa191366231751012
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou VA, Mok TS, Han JY, et al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann Oncol. 2020;31(11):1536–1544. doi:10.1016/j.annonc.2020.08.210032861806
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M–positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4(11):1527–1534. doi:10.1001/jamaoncol.2018.296930073261
   PubMed Web of Science ®Google Scholar
• Tang ZH, Lu JJ. Osimertinib resistance in non-small cell lung cancer: mechanisms and therapeutic strategies. Cancer Lett. 2018;420:242–246. doi:10.1016/j.canlet.2018.02.00429425688
   PubMed Web of Science ®Google Scholar
• Le X, Puri S, Negrao MV, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR -mutant NSCLC. Clin Cancer Res. 2018;24(24):6195–6203. doi:10.1158/1078-0432.CCR-18-154230228210
   PubMed Web of Science ®Google Scholar
• Mehlman C, Cadranel J, Rousseau-Bussac G, et al. Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study. Lung Cancer. 2019;137:149–156. doi:10.1016/j.lungcan.2019.09.01931600593
   PubMed Web of Science ®Google Scholar
• Del Re M, Crucitta S, Gianfilippo G, et al. Understanding the mechanisms of resistance in EGFR-positive NSCLC: from tissue to liquid biopsy to guide treatment strategy. Int J Mol Sci. 2019;20(16):20. doi:10.3390/ijms20163951
   Web of Science ®Google Scholar
• Wu Z, Yang Z, Li CS, et al. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC. Cancer Med. 2019;8(3):910–919. doi:10.1002/cam4.193530767431
   PubMed Web of Science ®Google Scholar
• Cao W, Wu W, Yan M, et al. Multiple region whole-exome sequencing reveals dramatically evolving intratumor genomic heterogeneity in esophageal squamous cell carcinoma. Oncogenesis. 2015;4(11):e175. doi:10.1038/oncsis.2015.3426619400
   PubMed Web of Science ®Google Scholar
• Ho CC, Liao WY, Lin CA, et al. Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib. J Thorac Oncol. 2017;12(3):567–572. doi:10.1016/j.jtho.2016.11.223127923714
   PubMed Web of Science ®Google Scholar
• Chabon JJ, Simmons AD, Lovejoy AF, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7(1):11815. doi:10.1038/ncomms1181527283993
   PubMed Web of Science ®Google Scholar
• Lee J, Shim JH, Park WY, et al. Rare mechanism of acquired resistance to osimertinib in korean patients with EGFR-mutated non-small cell lung cancer. Cancer Res Treat. 2019;51(1):408–412. doi:10.4143/crt.2018.13829807405
   PubMed Web of Science ®Google Scholar
• Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–1312. doi:10.1101/gad.165370818483217
   PubMed Web of Science ®Google Scholar
• Yang H, Wang F, Deng Q, et al. Predictive and prognostic value of phosphorylated c-KIT and PDGFRA in advanced non-small cell lung cancer harboring ALK fusion. Oncol Lett. 2019;17(3):3071–3076. doi:10.3892/ol.2019.997230867736
   PubMed Web of Science ®Google Scholar
• McCoach CE, Le AT, Gowan K, et al. Resistance mechanisms to targeted therapies in ROS1 + and ALK + non–small cell lung cancer. Clin Cancer Res. 2018;24(14):3334–3347. doi:10.1158/1078-0432.CCR-17-245229636358
   PubMed Web of Science ®Google Scholar
• Antonescu CR, DeMatteo RP. CCR 20th anniversary commentary: a genetic mechanism of imatinib resistance in gastrointestinal stromal tumor—where are we a decade later? Clin Cancer Res. 2015;21(15):3363–3365. doi:10.1158/1078-0432.CCR-14-312026240289
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773:1263–1284.17126425
   PubMed Web of Science ®Google Scholar
• Steelman LS, Franklin RA, Abrams SL, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25(7):1080–1094. doi:10.1038/leu.2011.6621494257
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Kajiho H, Sakurai K, et al. Tyr-phosphorylation signals translocate RIN3, the small GTPase Rab5-GEF, to early endocytic vesicles. Biochem Biophys Res Commun. 2008;372(1):168–172. doi:10.1016/j.bbrc.2008.05.02718486601
   PubMed Web of Science ®Google Scholar
• Wang Q, Gao Y, Tang Y, et al. Prognostic significance of RIN1 gene expression in human non-small cell lung cancer. Acta Histochem. 2012;114(5):463–468. doi:10.1016/j.acthis.2011.08.00821925717
   PubMed Web of Science ®Google Scholar
• Tomshine JC, Severson SR, Wigle DA, et al. Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1. J Biol Chem. 2009;284(39):26331–26339. doi:10.1074/jbc.M109.03351419570984
   PubMed Web of Science ®Google Scholar
• Zhou B, Zhu W, Jiang X, et al. RASAL2 plays inconsistent roles in different cancers. Front Oncol. 2019;9:1235. doi:10.3389/fonc.2019.0123531799194
   PubMed Web of Science ®Google Scholar
• Pan Y, Tong JHM, Lung RWM, et al. RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer. Mol Cancer. 2018;17(1):102. doi:10.1186/s12943-018-0853-630037330
   PubMed Web of Science ®Google Scholar
• Li N, Li S. RASAL2 promotes lung cancer metastasis through epithelial-mesenchymal transition. Biochem Biophys Res Commun. 2014;455(3–4):358–362. doi:10.1016/j.bbrc.2014.11.02025446096
   PubMed Web of Science ®Google Scholar
• Tong X, Tanino R, Sun R, et al. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer. Respir Res. 2019;20(1):270. doi:10.1186/s12931-019-1244-231791326
   PubMed Web of Science ®Google Scholar
• Si X, Gao Z, Xu F, et al. SOX2 upregulates side population cells and enhances their chemoresistant ability by transactivating ABCC1 expression contributing to intrinsic resistance to paclitaxel in melanoma. Mol Carcinog. 2020;59(3):257–264. doi:10.1002/mc.2314831883360
   PubMed Web of Science ®Google Scholar
• Li Y, Liu Y, Ren J, et al. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol. 2018;138(3):499–508. doi:10.1007/s11060-018-2835-329876787
   PubMed Web of Science ®Google Scholar